Haleon PLC has been making significant strides in the biotech sector. The pharmaceutical company has been implementing a
strategic share buyback program which reflects its commitment to capital management.
Pfizer, a major stakeholder, has finalized its
exit from Haleon by offloading its final shares, a move that reflected positively on the
stock market. The sale, worth around $3.2 billion, underscored the significant value of Haleon as a consumer healthcare giant. On the other hand,
BlackRock has increased its stakes in Haleon, suggesting a favorable outlook for the firm. Haleon's objective for revenue growth is set for 2025 with stronger performances expected in the latter half. Despite some
stock market volatility and fluctuating ratings from financial institutions, Haleon has remained a defensive play in the stock market. The company has been awarded for its strong business profile as reflected in an upgrade by
Moody's. Furthermore, Haleon is intensifying its global presence by fully taking over its Chinese JV TSKF.
HSBC maintains a GBP4.20 target on the stock, while
Jefferies maintains a Buy rating with a target of GBP4.50.
Haleon Stocks News Analytics from Mon, 05 Aug 2024 07:00:00 GMT to Thu, 24 Apr 2025 11:29:15 GMT -
Rating 6
- Innovation 5
- Information 9
- Rumor 1
